期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

塞来昔布联合干扰素α对K562／A02细胞增殖的影响及其机制 被引量：1

原文传递
导出
摘要 尽管酪氨酸激酶抑制剂已成为治疗慢性髓系白血病（CML）的一线药物，但干扰素α（IFN-α）在CML治疗中仍不可或缺，因为IFN-α治疗可使27％的患者获完全细胞遗传学缓解（CCR），约50％获CCR的患者可长期保持CCR，中止IFN-α治疗后仍有部分患者可持续保持CCR，而酪氨酸激酶抑制剂治疗获CCR后一旦停药，几乎所有患者都会复发。
作者 郭华 曹维克 刘定胜 邓之奎 李元媛 朱家斌 李玉峰
机构地区 南京医科大学附属淮安第一医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2011年第6期408-409,共2页 Chinese Journal of Hematology
基金 南京医科大学科技发展基金
关键词 K562/A02 干扰素Α 细胞增殖 塞来昔布 酪氨酸激酶抑制剂 IFN-Α 慢性髓系白血病 细胞遗传学
分类号 R965 [医药卫生—药理学]
  • 相关文献

参考文献6

二级参考文献37

  • 1Oscier D,Fegan C,Hillman P,Illide T,Johnson S,Maguir P,Matutes M,Milligan D,孙蕾,高举.慢性淋巴细胞白血病诊治指南[J].国外医学（输血及血液学分册）,2005,28(1):1-7. 被引量：6
  • 2徐卫,李建勇,吴雨洁,盛瑞兰,陆风翔.29例慢性淋巴细胞白血病Ki-67和Bcl-2的表达及临床意义[J].中国实验血液学杂志,2006,14(3):464-467. 被引量：7
  • 3李睿娟,龚凡杰,张广森.塞来昔布对K562白血病细胞的细胞毒作用及与伊马替尼的协同效应[J].中华医学杂志,2006,86(20):1417-1420. 被引量：2
  • 4Nakayama S, Nagamura-Inoue T, Yokoyama K, et al. Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Int J Hematol, 2007 ;86 (3) :208 - 211.
  • 5Giles FJ, Kantarjian HM, Bekele BN, et al. Bone marrow cyclooxygenase-2 revels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol, 2002 ;119 ( 1 ) :38 -45.
  • 6Peng HL, Zhang GS, Liu JH, et al. Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol, 2008 ;87 (2) : 121 - 129.
  • 7Arunasree KM, Roy KR, Anilkumar K, et al. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res, 2008;32(6) :855 - 864.
  • 8Bonifazi F, de Vivo A, Rosti G,et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood,2001 ;98 (10) :3074 - 3081.
  • 9Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long- term prognosis. Cancer, 2003 ;97 (4) : 1033 - 1041.
  • 10Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 2007 ;109( 11 ) :4686 -4692.

共引文献10

同被引文献21

  • 1SANEJA A, KHARE V, ALAM N, et al. Advances in P-glycoprotein-hased approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance [ J ] . Expert Opin Drug Deliv, 2014, 11(1): 121-138.
  • 2DARBY R A, CALLAGHAN R, MCMAHON R M. P-glycoprotein inhibition: the past, the present and the future [ J ]. Curt Drug Metab, 2011, 12(8): 722-731.
  • 3HARRIS R E. Cycloozygenase-2 (COX-2) and inflanamogenesis of cancer [ J ] . Subcell Biochem, 2007, 42(1): 93-126.
  • 4NINOMIYA I, NAGAI N, OYAMA K, et al. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum [ J ] . Oncol Rep, 2012, 28(3): 777-784.
  • 5YAN Y X, LI W Z, HUANG Y Q, et al. The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function [J]. Prostaglandins Other Lipid Mediat, 2012, 97(1-2): 29-35.
  • 6BOCCA C, BOZZO F, BASSIGNANA A, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance [ J ] . Nature, 2015, 517(7533): 209-213.
  • 7CHEN S T, THOMAS S, GAFFNEY K J, et al. Cytotoxic effects of celecoxib on Raji lymphoma cel|s correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2 [ J ] . Leuk Res. 2010, 34(2): 250-253.
  • 8GALLOUET A S, TRAVERT M, BRESSON-BEPOLDIN L, et al. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis [ J 1 - Clin Cancer Res, 2014, 20(10): 2663-2673.
  • 9LIU D B, LONG G X, MEI Q,et al. Anticancer effects of celecoxib through inhibition of STAT3 phosphorylation and AKT phosphorylation in nasopharyngeal carcinoma cell lines [ J 1 . Pharmazie, 2014, 69(5): 358-361.
  • 10NG S Y, DAVIDS M S. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma [ J -. Clin Adv Hematol Oncol, 2014, 12(4): 224-229.

引证文献1

二级引证文献5

中华血液学杂志
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部